---
run_id: halo-evidence-vs-diagnosis-validation-v9-substrate-workflow-06
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: substrate_workflow
run_number: 6
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 603
prompt_source: condition packet (substrate_workflow) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a substrate preamble plus three reviewed source cards, then the frozen Advisor prompt - see run-packet.md
source_packet_sha256: 8c1fbdb9b2af9238d4533dece4ffc185fda2e1f7ecb6008913243d23d9a67c63
condition_packet_sha256: 8c1fbdb9b2af9238d4533dece4ffc185fda2e1f7ecb6008913243d23d9a67c63
output_file: model-outputs/substrate_workflow-06.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - substrate_workflow (run 06)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `substrate_workflow`, run 6 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 603, on the frozen condition packet.

## Output

**Recommendation:** Commit to the **Claim File Review**.

**Reasoning:**
Your current evidence is heavily contaminated by "performance-aware attribution" (BK-0048-card-001). The executive team is attributing the strong quarter to product "discipline" and "alignment," but the data suggests this is a lagging effect of temporary bundle pricing and sales pitches rather than product value.

Furthermore, your current metrics (usage spikes and reduced support tickets) are "broad activity metrics" that may be failing to disconfirm the favored story (BK-0007-card-001). The 39% usage increase is driven by managers auditing closed files, not adjusters solving active claims; the drop in support tickets is likely a routing shift to training channels.

The **Claim File Review** is the only option that provides a "load-bearing diagnosis" (BK-0001-card-001) of the actual problem. By inspecting whether suggestions were accepted, overridden, or "impossible to explain," you move from activity metrics to behavioral evidence. This directly tests the critical uncertainty: is DraftPath providing a workflow utility that adjusters value, or is it a "feature shipment" that looks like progress but fails in practice (especially in the health-liability segment)?

*   The *Usage Quality Sprint* only measures return rates (activity), not value.
*   The *Commercial Cleanroom* tests sales efficacy, not product-market fit.
*   *Scaling broadly* risks compounding a failure if the core utility is absent.

**Strongest Reason Against:**
This approach is slow and qualitative. It provides a "small set" of evidence rather than the statistical confidence of a Cleanroom or Sprint, which may make it difficult to convince an executive team currently intoxicated by a "surprisingly strong quarter" and rising expansion bookings.

**Evidence That Would Change My Mind:**
I would pivot to the *Commercial Cleanroom* if you could prove that the "impossible to explain" feedback in the health-liability segment is a peripheral edge case rather than a systemic failure of the product's logic. If evidence emerged that front-line adjusters are actually accepting the majority of suggestions but simply lacking the training to document them, the problem shifts from a *product-utility* diagnosis to a *commercial-enablement* diagnosis.
